PRESS-RELEASE filed May 7, 2026 at 08:00 ET
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline is the FDA acceptance of NDAs for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (priority review, PDUFA Sep 27, 2026), positioning for two U.S. launches within eight months. The company also reported a 77% placebo-adjusted seizure reduction for elsunersen in early-seizure-onset SCN2A-DEE and maintains a $1.4B cash runway into 2028, funding multiple upcoming catalysts including POWER1 (FOS) topline in Q2 2026 and EMERALD (broad DEEs) in Q4 2026.